The safety profile was acceptable80.Phase We ("type":"clinical-trial","attrs":"text":"NCT01138033","term_id":"NCT01138033"NCT01138033)SingleCompletedSolid tumorsGSK2256098 comes with an acceptable basic safety profile and offers clinical activity in sufferers with mesothelioma, people that have merlin loss81 particularly.Phase We ("type":"clinical-trial","attrs":"text":"NCT00996671","term_id":"NCT00996671"NCT00996671)SingleCompletedHealthy volunteersUnpostedPhase II ("type":"clinical-trial","attrs":"text":"NCT02523014","term_id":"NCT02523014"NCT02523014)SingleSuspended (not currently available to individual enrollment)Intracranial meningioma, repeated meningioma with NF2 gene mutationUnpostedPhase II ("type":"clinical-trial","attrs":"text":"NCT02428270","term_id":"NCT02428270"NCT02428270)Combinatory (with trametinib)Dynamic, not recruitingAdvanced pancreatic cancerThe GSK2256098 and trametinib mixture was very well tolerated but had not been effective in sufferers82.VS-4718VS-4718 blocks fibronectin-stimulated FAK autophosphorylation at Tyr397Phase I ("type":"clinical-trial","attrs":"text":"NCT02651727","term_id":"NCT02651727"NCT02651727)Combinatory (with paclitaxel and SYP-5 gemcitabine)TerminatedPancreatic cancerUnpostedPhase I ("type":"clinical-trial","attrs":"text":"NCT01849744","term_id":"NCT01849744"NCT01849744)SingleTerminated (sponsors decision to deprioritize this program)Nonhematologic malignancies, metastatic cancerUnpostedPhase I ("type":"clinical-trial","attrs":"text":"NCT02215629","term_id":"NCT02215629"NCT02215629)SingleWithdrawnAcute myeloid leukemia, B cell acute lymphoblastic leukemiaCVS-6063 (defatinib)VS-6063 inhibits FAK phosphorylation on the Tyr397Phase I ("type":"clinical-trial","attrs":"text":"NCT00787033","term_id":"NCT00787033"NCT00787033)SingleCompletedAdvanced nonhematologic malignanciesVS-6063 comes with an acceptable basic safety profile. progression. an infection may be the leading reason…